Latest news with #MiYOSMART
Business Upturn
3 days ago
- Business
- Business Upturn
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Salt Lake City, United States: Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years 1 Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children 2 A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3 HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said 'This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.' The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 'Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child.' said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' saidDr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.' For the abstracts presented at ARVO 2025, please visit Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
3 days ago
- Business
- Yahoo
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years1 Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children2 A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3 SALT LAKE CITY, June 12, 2025--(BUSINESS WIRE)--HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said "This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future." The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 "Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 "With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent," said Dr. Vlasak. "With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations." For the abstracts presented at ARVO 2025, please visit Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries. View source version on Contacts Pamela Pedrucci PR, Media and External Comms Director HOYA Vision Care Sign in to access your portfolio
Business Wire
3 days ago
- Health
- Business Wire
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
SALT LAKE CITY--(BUSINESS WIRE)--HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up. 1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said " This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.' The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children. 2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment. 4 "Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research. 3 'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' said Dr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.' For the abstracts presented at ARVO 2025, please visit *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.
Yahoo
02-06-2025
- Business
- Yahoo
HOYA Vision Care Acquires Centennial Optical
Acquisition Strengthens Service to the Canadian Market MISSISSAUGA, ON, June 2, 2025 /PRNewswire/ -- HOYA Vision Care is proud to announce the acquisition of Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. The acquisition represents a significant opportunity to add to Centennial Optical's solid foundation and leverage it with HOYA's resources and technologies. The complementary capabilities of the two companies will elevate their ability to better serve the Canadian market. "We continuously seek new opportunities to deliver greater value and drive innovation," said Steven Haifawi, President of HOYA Vision Care Canada. "This strategic investment expands both our companies' capabilities and enhances our competitive positions in the market while strengthening our partnerships with customers across Canada." "We carefully considered the future of our business, our customers, and our employees," said Allen Nightingale, President of Centennial Optical. "What stood out about HOYA was more than just their industry leadership; it was their alignment with our culture, values, and mission. HOYA shares our commitment to innovation, integrity, and customer focused service, which made them the right partner for Centennial's next chapter." HOYA is committed to maintaining the high level of service and support Centennial Optical is known for, while leveraging synergies to further improve customer experience in the long-term. To learn more, visit HOYA Vision Care Canada online (English and French). About HOYA Corporation Founded in 1941 in Tokyo, Japan, HOYA is a global technology and med-tech company, and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of healthcare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of over 35,000 people. For more information, please visit About HOYA Vision Care For over 60 years, HOYA Vision Care has been a global leader in the eyeglass lens industry. The company is dedicated to providing innovative vision care solutions for every stage of a patient's life. With a presence in over 50 countries, HOYA Vision Care has a leading position in myopia management category and a proven expertise in advanced lens designs, high performance photochromic technologies and high-quality AR coatings. HOYA Vision Care's solid market portfolio includes HOYA, Vision Ease, SEIKO and PENTAX optical lenses, as well as innovative products such as MiYOSMART myopia control lenses for children, Hoyalux iD MySelf individualized progressive lenses and the Sensity range of photochromic lenses. The company employs over 20,000 employees worldwide with large scale production facilities in Asia, Europe, and the US and 38 local Rx laboratories globally. For more information, please visit About Centennial Optical Founded in 1967, Centennial sells optical goods and services to Canadian Eye Care Professionals (Optometrists and Opticians), optical laboratories and optical retailers. For more information, please visit View original content to download multimedia: SOURCE HOYA Vision Care, North America Sign in to access your portfolio
Cision Canada
02-06-2025
- Business
- Cision Canada
HOYA Vision Care Acquires Centennial Optical Français
Acquisition Strengthens Service to the Canadian Market MISSISSAUGA, ON, June 2, 2025 /CNW/ -- HOYA Vision Care is proud to announce the acquisition of Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. The acquisition represents a significant opportunity to add to Centennial Optical's solid foundation and leverage it with HOYA's resources and technologies. The complementary capabilities of the two companies will elevate their ability to better serve the Canadian market. "We continuously seek new opportunities to deliver greater value and drive innovation," said Steven Haifawi, President of HOYA Vision Care Canada. "This strategic investment expands both our companies' capabilities and enhances our competitive positions in the market while strengthening our partnerships with customers across Canada." "We carefully considered the future of our business, our customers, and our employees," said Allen Nightingale, President of Centennial Optical. "What stood out about HOYA was more than just their industry leadership; it was their alignment with our culture, values, and mission. HOYA shares our commitment to innovation, integrity, and customer focused service, which made them the right partner for Centennial's next chapter." HOYA is committed to maintaining the high level of service and support Centennial Optical is known for, while leveraging synergies to further improve customer experience in the long-term. To learn more, visit HOYA Vision Care Canada online (English and French). About HOYA Corporation Founded in 1941 in Tokyo, Japan, HOYA is a global technology and med-tech company, and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of healthcare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of over 35,000 people. For more information, please visit About HOYA Vision Care For over 60 years, HOYA Vision Care has been a global leader in the eyeglass lens industry. The company is dedicated to providing innovative vision care solutions for every stage of a patient's life. With a presence in over 50 countries, HOYA Vision Care has a leading position in myopia management category and a proven expertise in advanced lens designs, high performance photochromic technologies and high-quality AR coatings. HOYA Vision Care's solid market portfolio includes HOYA, Vision Ease, SEIKO and PENTAX optical lenses, as well as innovative products such as MiYOSMART myopia control lenses for children, Hoyalux iD MySelf individualized progressive lenses and the Sensity range of photochromic lenses. The company employs over 20,000 employees worldwide with large scale production facilities in Asia, Europe, and the US and 38 local Rx laboratories globally. For more information, please visit
